Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Agenesis

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44363   clinical trials with a EudraCT protocol, of which   7387   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    46 result(s) found for: Agenesis. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2014-002710-23 Sponsor Protocol Number: P140203 Start Date*: Information not available in EudraCT
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title:
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    18.0 10010331 - Congenital, familial and genetic disorders 10054935 Aicardi's syndrome PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2025-000001-16 Sponsor Protocol Number: I4V-JE-JAJE Start Date*: 2025-02-19
    Sponsor Name:Eli Lilly and Company
    Full Title: A Phase 2/3, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Baricitinib in Adult and Pediatric Japanese Patients with NNS/CANDLE, SAVI, and AGS
    Medical condition: Nakajo-Nishimura Syndrome, Chronic Atypical Neutrophilic Dermatosis with Lipodystrophy and Elevated Temperature Syndrome, STING-Associated Vasculopathy with Onset in Infancy, Aicardi Goutieres Sy...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10073960 CANDLE syndrome PT
    21.1 10047065 - Vascular disorders 10047115 Vasculitis PT
    27.1 10010331 - Congenital, familial and genetic disorders 10054935 Aicardi's syndrome PT
    Population Age: Children, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2019-001188-58 Sponsor Protocol Number: IDIT001 Start Date*: 2022-02-16
    Sponsor Name:Göteborgs Universitet
    Full Title: The effect of anti-IL17 in new-onset type 1 diabetes: a randomized, double-blind, placebo-controlled trial
    Medical condition: Type 1 diabetes
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2007-005166-12 Sponsor Protocol Number: HMPL-004-US-02 Start Date*: 2008-07-29
    Sponsor Name:Hutchison MediPharma Enterprises Limited
    Full Title: A Phase II, Randomized, Multi-Centre, Double-Blind, Placebo-Controlled Trial of HMPL-004 in Patients with Mild to Moderate Active Ulcerative Colitis with or without Mesalamine
    Medical condition: active mild to moderate ulcerative colitis defined as a Mayo clinical score of 4-10 points
    Disease: Version SOC Term Classification Code Term Level
    9.1 10066678 Acute ulcerative colitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-003710-13 Sponsor Protocol Number: Pro-Tac Start Date*: Information not available in EudraCT
    Sponsor Name:University Hospital Essen
    Full Title: A multi-center interventional study to assess pharmacokinetics, effectiveness and tolerability of prolonged-release Tacrolimus after Paediatric Kidney Transplantation
    Medical condition: Caucasian paediatric kidney transplant recipients
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-003413-35 Sponsor Protocol Number: WN42349 Start Date*: 2020-12-07
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A MULTICENTER, SINGLE ARM, OPEN-LABEL STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF SATRALIZUMAB IN PATIENTS WITH NEUROMYELITIS OPTICA SPECTRUM DISORDER (NMOSD)
    Medical condition: Neuromyelitis Optic Spectrum Disorder
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10077875 Neuromyelitis optica spectrum disorder PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) HU (Completed) BG (Completed) PL (Completed) IT (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2018-003365-34 Sponsor Protocol Number: I4V-MC-JAIV Start Date*: 2019-05-02
    Sponsor Name:Eli Lilly and Company
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study Evaluating the Efficacy and Safety of Baricitinib (LY3009104) in Patients with Primary Biliary Cholangitis Who Have an Inadeq...
    Medical condition: Primary Biliary Cholangitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10019805 - Hepatobiliary disorders 10008604 Cholangitis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-000087-15 Sponsor Protocol Number: CRd Start Date*: 2012-03-30
    Sponsor Name:FONDAZIONE NEOPLASIE SANGUE ONLUS
    Full Title: A PHASE II, MULTI-CENTER, OPEN LABEL STUDY OF CYCLOPHOSPHAMIDE IN MULTIPLE MYELOMA PATIENTS WITH BIOCHEMICAL PROGRESSION DURING LENALIDOMIDE-DEXAMETHASONE TREATMENT FOR RELAPSED/REFRACTORY MULTIPLE...
    Medical condition: RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-000014-38 Sponsor Protocol Number: THX-G18-001 Start Date*: 2018-08-02
    Sponsor Name:Therapix Biosciences Ltd.
    Full Title: A Randomized, Double-Blind, Placebo Controlled Proof of Concept Study to Evaluate the Safety, Tolerability and Efficacy of Daily Oral THX-110 in Treating Adults with Tourette Syndrome (“ENTOURAGE”)
    Medical condition: Tourette Syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10044127 Tourette's syndrome LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2015-000287-34 Sponsor Protocol Number: ARO-012 Start Date*: 2017-05-30
    Sponsor Name:Arog Pharmaceuticals, Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Trial of Crenolanib in Subjects with Advanced or Metastatic Gastrointestinal Stromal Tumors with a D842V Mutation in the PDGFRA Gene.
    Medical condition: Advanced or metastatic gastrointestinal stromal tumor (GIST)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10062427 Gastrointestinal stromal tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing) ES (Ongoing) GB (GB - no longer in EU/EEA) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-007698-22 Sponsor Protocol Number: R2-CHOP Start Date*: 2008-07-10
    Sponsor Name:GELARC
    Full Title: A PHASE IB/II STUDY OF ESCALATING DOSES OF REVLIMID IN ASSOCIATION WITH R-CHOP (R2-CHOP) IN THE TREATMENT OF B-CELL LYMPHOMA
    Medical condition: B cell lymphoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2011-003372-37 Sponsor Protocol Number: ET11-072 Start Date*: 2014-06-04
    Sponsor Name:CENTRE LEON BERARD
    Full Title: An international, randomized, open-label Phase I/II study of vismodegib in combination with temozolomide versus temozolomide alone in adult patients with recurrent or refractory medulloblastoma pre...
    Medical condition: Recurrent, progressive or refractory medulloblastoma with activation of the SHH pathway
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066594 Medulloblastoma recurrent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2017-000394-36 Sponsor Protocol Number: M17-05-LCZ-ARNI Start Date*: 2017-12-20
    Sponsor Name:Hannover Medical School
    Full Title: Influences of angiotensin-neprilysin inhibition with Sacubitril/Valsartan (ENTRESTO®) on centrally generated sympathetic activity in heart failure patients
    Medical condition: Chronic heart failure with reduced left ventricular ejection fraction (NYHA II-III)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10078289 Heart failure with reduced ejection fraction LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-001936-86 Sponsor Protocol Number: COMET Start Date*: 2020-10-19
    Sponsor Name:Hannover Medical School
    Full Title: A prospective, randomized, open label Phase 2 clinical trial to evaluate superiority of anti-SARS-CoV-2 convalescent plasma versus standard-of-care in hospitalized patients with mild COVID-19
    Medical condition: Hospitalized patients with mild SARS-CoV-2 infection (WHO R&D Blueprint Ordinal Scale for Clinical Improvement = 3 or 4)
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004862 10084272 SARS-CoV-2 infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-005101-39 Sponsor Protocol Number: ORION-LVAD-1 Start Date*: 2018-06-06
    Sponsor Name:Hannover Medical School
    Full Title: A phase IV study to explore the safety of ORal IrON supplementation with ferric maltol in treating iron deficiency in patients with heart failure carrying Left Ventricular Assist Devices (ORION-LVA...
    Medical condition: Patients with iron deficiency anemia and heart failure carrying left ventricular assist devices (LVAD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10022974 Iron deficiency anemia LLT
    20.0 100000004849 10008908 Chronic heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-000564-42 Sponsor Protocol Number: CANNA-TICS Start Date*: 2017-06-14
    Sponsor Name:Hannover Medical School
    Full Title: A randomized multi-centre double-blind placebo controlled trial to demonstrate the efficacy and safety of nabiximols in the treatment of adults with chronic tic disorders (CANNA-TICS)
    Medical condition: Chronic tic disorders and Tourette syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004873 10043835 Tic disorders HLT
    20.0 100000004850 10018269 Gilles de la Tourette syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-004495-60 Sponsor Protocol Number: I4V-MC-JAHU Start Date*: 2019-09-24
    Sponsor Name:Eli Lilly and Company
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Withdrawal, Safety and Efficacy Study of Oral Baricitinib in Patients from 1 Year to Less than 18 Years Old with Systemic Juvenile Idiopathic Arthrit...
    Medical condition: Systemic Juvenile Idiopathic Arthritis (sJIA)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004859 10079454 Systemic juvenile idiopathic arthritis LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) GB (GB - no longer in EU/EEA) DE (Prematurely Ended) AT (Trial now transitioned) BE (Trial now transitioned) CZ (Trial now transitioned) PL (Trial now transitioned) DK (Prematurely Ended) ES (Ongoing) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-004422-29 Sponsor Protocol Number: I8F-MC-GPGL(b) Start Date*: 2019-07-26
    Sponsor Name:Eli Lilly and Company
    Full Title: A Phase 3, Randomized, Open-Label Trial Comparing Efficacy and Safety of Tirzepatide versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Patients with Type 2 Diabetes (SURPASS-2)
    Medical condition: Type 2 diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2016-005100-26 Sponsor Protocol Number: ORION-PH-1 Start Date*: 2017-10-09
    Sponsor Name:Hannover Medical School
    Full Title: A pilot Study to explore safety, tolerability and efficacy of ORal IrON supplementation with ferric maltol in treating iron deficiency in patients with pulmonary hypertension and iron deficiency an...
    Medical condition: Patients with iron deficiency anemia and pulmonary hypertension
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10022974 Iron deficiency anemia LLT
    20.0 100000004855 10037401 Pulmonary hypertensions HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2022-003526-50 Sponsor Protocol Number: HACOL-ACS Start Date*: 2023-05-09
    Sponsor Name:Hannover Medical School
    Full Title: A prospective, interventional, single-center, single-arm study to assess the effectiveness of Bempedoic acid to achieve LDL-cholesterol targets in patients following ST-elevation or Non-ST-elevatio...
    Medical condition: Patients following acute percutaneous coronary intervention for STEMI or NSTEMI insufficiently treated with high-intensity oral lipid lowering therapy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10064345 ST segment elevation myocardial infarction LLT
    20.0 10007541 - Cardiac disorders 10064347 Non ST segment elevation myocardial infarction LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue Nov 04 09:20:27 CET 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA